ABT-199 & Ibrutinib in Mantle Cell Lymphoma (AIM) (AIM)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02471391 |
Recruitment Status :
Active, not recruiting
First Posted : June 15, 2015
Last Update Posted : May 5, 2022
|
Sponsor:
Peter MacCallum Cancer Centre, Australia
Information provided by (Responsible Party):
Peter MacCallum Cancer Centre, Australia
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : | Active, not recruiting |
---|---|
Estimated Primary Completion Date : | June 2023 |
Estimated Study Completion Date : | June 2023 |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):